title: Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries.
abstract: The aim of this survey, which was part of an English-French project supported by the Commission of the European Communities, was to compare access to HIV post-exposure prophylaxis (PEP) in the occupational and non-occupational contexts in 27 European countries. A protocol was designed in May 1998 in collaboration with all country consultants. Data were collected at country level by each consultant through interviews, review of local and national recommendations and results of national or local surveys. The final comparative analysis was carried out from the individual country reports and a review of the literature. The large majority of European countries have detailed procedures regarding occupational PEP: 20/27 have produced national guidelines, three have adopted the US CDC recommendations and only four have no official recommendations. Although no standard protocol exists, the more common one is a four-week implementation of a triple combination therapy. In the context of non-occupational exposure to HIV, only five countries have guidelines with specific recommendations and one country has adopted the CDC recommendations. In the majority of cases (13 countries), PEP is never recommended but is only available in a few circumstances, sometimes with major limitations. In the last eight countries, such PEP is not currently available. Although the estimations of HIV transmission risks in occupational and non-occupational contexts are really comparables, easy access to PEP after accidental sexual or blood exposures is not guaranteed for the general population in the majority of European countries.
authors.affiliation: Regional Center for Disease Control of South Eastern France, ORS PACA, Marseille, France. rey@marseille.inserm.fr
authors.forename: D
authors.initials: D
authors.lastname: Rey
authors.forename: M K
authors.initials: MK
authors.lastname: Bendiane
authors.forename: J P
authors.initials: JP
authors.lastname: Moatti
authors.forename: K
authors.initials: K
authors.lastname: Wellings
authors.forename: R
authors.initials: R
authors.lastname: Danziger
authors.forename: W
authors.initials: W
authors.lastname: MacDowall
mesh_terms: D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005060:Europe; D015658:HIV Infections / Q000191:economics / Q000517:prevention & control* / Q000635:transmission; D017048:Health Care Costs; D006291:Health Policy; D006801:Humans; D016273:Occupational Exposure; D017410:Practice Guidelines as Topic; D011292:Premedication; D012309:Risk-Taking
chemical_list: D019380:Anti-HIV Agents